[1] 黄敬泽, 张闿珍, 王健, HUANG Jingze, ZHANG Kaizhen, WANG Jian. 外周血循环内皮细胞、血浆内皮素与糖尿病视网膜病变的关系 [J]. 中华眼底病杂志 2000.
[2] 胡蜀红, 张建华, 蔡仕林. 糖尿病视网膜病变与血浆内皮素的关系 [J]. 临床荟萃 2003.doi:10.3969/j.issn.1004-583X.2003.12.007
[3] 陈百华, 姜德咏, 唐罗生. 糖基化终产物对牛视网膜毛细血管周细胞内抗氧化能力的影响 [J]. 中华眼底病杂志 2002.
[4] Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. [J]. The Lancet 2010, 9735(9735).
[5] KOLLIAS A N, ULBIG M W. Diabetic retinopathy:early diagnosis and effective treatment [J]. Deutsches Aerzteblatt International 2010, 107(05).
[6] Early Treatment Diabetic Retinopathy Study Research Group. Fluoreocein angiographic risk factors for progression of diabetic retinopathy [J]. Ophthalmology 1991, 98(05).
[7] ADAMIS A P, MILLER J W, BERNAL M T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy [J]. American Journal of Ophthalmology 1994, 118(04).
[8] HOFMAN P, VAN BLIJSWIJK B C, GAILLARD P J. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina:new insights into the pathogenesis of capillary nonperfusion [J]. Archives of Ophthalmology 2001, 119(06).
[9] KUROKI M, KAWAKAMI M. Diabetic retinopathy-the mechinisms of the ocular nevascularization and the development of antiangiogemic drugs [J]. Nippon Rinsho/Japanese Journal of Clinical Medicine 1999, 57(03).
[10] KOHNER E M, PATEL V, RASSAM S M. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy [J]. Diabetes 1995, 44(06).
[11] CHAKRABARTI S, GAN X T, MERRY A. Augmented retinal endothelin-1, endothelin-3, endothelinA and endothelinB gene expression in chronic diabetes [J]. Current Eye Research 1998, 17(03).
[12] CHAKRABARTI S, SIMA A A. Endothelin-1 and endothelin-3-like immunoreactivity in the eyes of diabetic and non-diabetic BB/W rats [J]. Diabetes Research and Clinical Practice 1997, 37(02).
[13] Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N. Erythropoietin both protects from and reverses experimental diabetic neuropathy [J]. Proceedings of the National Academy of Sciences of the United States of America 2004, 3(3).
[14] ZHONG Yisheng, YAO Huiping, DENG Lianfu. Promotion of neurite outgrowth and protective effect of erythropoietin on the retinal neurons of rats [J]. Greefe's Archive for Clinical and Experimental Ophthalmology 2007, 245(12).
[15] ASENSIO-SANCHEZ V M, GóMEZ-RAMIREZ V, MORALES-GóMEZ I. Erythropeietin concentrations in the vitreous body from patients with proliferative diabetic retinopathy [J]. Archivos De La Sociedad Espanola De Oftalmologia 2008, 83(03).
[16] Kase S, Saito W, Ohgami K, Yoshida K, Furudate N, Saito A, Yokoi M, Kase M, Ohno S. [J]. British journal of ophthalmology 2007.
[17] NISHIMURA C, SAITO T, ITO T. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients [J]. Diabetologia 1994, 37(03).
[18] ELLIS E A, GUBERSKI D L, HUTSON B. Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat [J]. Nitric Oxide:Biology and Chemistry 2002, 6(03).
[19] BIERHAUS A, CHEVION S, CHEVIOU M. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells [J]. Diabetes 1997, 46(09).
[20] WATANABE D, SUZUMA K, SUZUMA I. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy [J]. American Journal of Ophthalmology 2005, 139(03).
[21] PETROVIC M G, KOROSEC P, KOSNIK M. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy [J]. Molecular Vision 2008, 30(14).
[22] AREVALO J F, GARCIA-AMARIS R A. Intravitreal bevacizumab for diabetic Retinopathy [J]. Current Diabetes Reviews 2009, 5(01).
[23] Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell SE, Aiello LP, Feener EP. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. [J]. Nature medicine 2007, 2(2).
[24] Einarsdottir AB, Stefansson E. Prevention of diabetic retinopathy. [J]. The Lancet 2009, 9672(9672).
[25] Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. [J]. Diabetes: A Journal of the American Diabetes Association 2006, 9(9).
[26] ADAMIS A P. Is diabetic retinopathy an inflammatory disease [J]. British Journal of Ophthalmology 2002, 86(04).
[27] Miyahara S, Kiryu J, Yamashiro K, Miyamoto K, Hirose F, Tamura H, Katsuta H, Nishijima K, Tsujikawa A, Honda Y. Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. [J]. American Journal of Pathology 2004, 5(5). |
